GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2009

Centocor to Optimize Its Antibody Candidates Using Xencor’s Technology

  • Xencor licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development for the optimization of Centocor’s antibody drug candidates. Under the multiyear agreement, Centocor will gain access to both the XmAb and Xtend technology platforms and has the right to develop and commercialize a specified number of optimized candidates. Xencor will receive license fees and is eligible to receive milestones and royalties on products commercialized from the collaboration.

    Xtend antibody technology platform helps enhance the serum half-life of immunoglobulin molecules. The XmAb platform can increase the potency of therapeutic antibodies by specifically engaging the body’s immune system against target antigen cells, according to Xencor.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?